Loading...

Home
ETF
NGEN

NGEN

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

NGEN News

NervGen's NVG-291 Shows Significant Improvement in Gait Quality

4d agoNewsfilter

Stock Futures Slightly Rise as Investors Monitor Iran Peace Talks

May 22 2026seekingalpha

NervGen Pharma Announces Public Offering of 24 Million Shares

May 22 2026seekingalpha

NervGen Pharma Announces Pricing of Public Offering

May 22 2026Newsfilter

NervGen Pharma Launches Public Offering of Shares and Warrants

May 21 2026seekingalpha

NervGen Pharma Reports Q1 Financial Results

May 18 2026seekingalpha

NervGen Pharma Appoints New CFO to Accelerate Growth

Apr 27 2026Newsfilter

NervGen Aligns with FDA on RESTORE Study Parameters for NVG-291

Apr 07 2026Newsfilter

NervGen Pharma Reports FY Loss with Cash Position Improvement

Mar 31 2026seekingalpha

NervGen Pharma Voluntarily Delists Common Shares

Mar 12 2026Yahoo Finance

NervGen Pharma Appoints New Executives to Enhance Leadership Team

Mar 04 2026Newsfilter

NervGen Pharma to Participate in Upcoming Investor Conferences

Feb 18 2026Newsfilter

NervGen Pharma Appoints New CEO Adam Rogers

Feb 09 2026seekingalpha

NervGen Pharma Approved for Nasdaq Listing, Advancing SCI Treatment Drug Development

Jan 08 2026NASDAQ.COM